Introduction:

The use of immunoglobulins as adjunctive therapy in septic shock becomes a therapeutic option as an immunomodulator, and as a blocking mechanism of apoptosis.

Method:

We reviewed retrospectively, patient’s charts with the diagnosis of septic shock on admission to the ICU, from August 1, 2014 to July 31, 2015. Two groups were formed, one with immunoglobulin as an adjuvant. We sought to measure the statistical survival through Kaplan-Meier analysis comparing its significance with Mantel-Cox.

Results:

The cohort was formed of 18 patients diagnosed with septic shock. Both groups were formed with 9 patients each. Group 1 (immunoglobulin): had a mortality of 22% with a median of survival of 15 days compared to the Group 2 (no immunoglobulin): mortality of 55% with a median of 8 days, with a statistically significant difference (p = 0.004).

Conclusions:

Our study showed that there was an increase in survival in patients receiving immunoglobulin compared to those without it. However, we believe that more prospective randomized trials should be made to recommend its use.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )